Although the beneficial effect of most H3R inverse agonists is inconclusive, pitolisant, an H3R antagonist developed by Schwartz et al. [16], was approved for the treatment of narcolepsy by the European Medical Agency in 2016 [17], emphasising the involvement of histamine concentration in brain functions. This evidence concerns the gene HRH3 and narcolepsy.